Abstract Objective: The purpose of this study was to investigate the relationship between the neutrophil-lymphocyte ratio (NLR), platelet distribution width (PDW) and prognostic nutrient index (PNI), and the prognosis of patients with advanced non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy.Methods: A total of 428 patients with advanced NSCLC treated with platinum-based chemotherapy between January 2015 and June 2019 were retrospectively analyzed. The patients were randomly divided into training set (n=300) and test set (n=128) in a ratio of 7:3, respectively. Clinical data and peripheral blood test results were collected within one week prior to the initiation of treatment to calculate PDW, NLR, and PNI. Receiver operating characteristic (ROC) curves were used to determine the optimal cut-off values of PLR, PDW, and PNI. Kaplan-Meier method and Cox regression analysis were used to evaluate the prognostic factors of advanced NSCLC treated with platinum-based chemotherapy. A Nomogram model was established for predicting the prognosis in advanced NSCLC treated with platinum-based chemotherapy. The test set was used for external validation of the prognostic model.Results: There was no significant difference in the proportion of clinical features between the training set and the test set (P＞0.05). The ROC curve analysis determined the optimal cut-off values of PLR, PDW, and PNI to be 3.07, 16.81, and 52.025, respectively. Univariate and multivariate analyses indicated that tumor type (P=0.038), tumor differentiation (P=0.014), NLR (P=0.001), PDW (P<0.001), and PNI (P=0.009) were independent prognostic factors for PFS in patients with advanced NSCLC patients treated with platinum-based chemotherapy. Tumor type (P=0.002), tumor differentiation (P=0.038), EGFR status (P=0.002), NLR (P=0.010), PDW (P=0.001), and PNI (P=0.002) were independent prognostic factors for overall survival (OS) in advanced NSCLC patients treated with platinum-based chemotherapy. The established nomogram was validated internally and externally. The results showed a good agreement between the predicted value and the actual value of the calibration curve.Conclusion: NLR, PDW, PNI, tumor type, and tumor differentiation are independent prognostic factors for PFS in advanced NSCLC patients treated with platinum-based chemotherapy. NLR, PDW, PNI, tumor type, tumor differentiation, and EGFR status are independent prognostic factors for OS in advanced NSCLC patients treated with platinum-based chemotherapy. The established model has an application value in predicting the prognosis of advanced NSCLC patients treated with platinum-based chemotherapy.
Background Cervical cancer (CC) is a prevalent malignancy in women and ranks fourth in global cancer-related mortality. The prognosis for women with metastatic or recurring cervical cancer is unfavorable. Camrelizumab is a humanized high-affinity IgG4-kappa monoclonal antibody targeting programmed cell death 1 (PD-1), which has been progressively documented as a therapy for advanced cervical cancer with good result metrics. Nonetheless, a comprehensive investigation of Camrelizumab’s efficacy in treating cervical cancer has yet to be conducted. Methods We conducted a search across PubMed, Ovid Medline, Embase, Web of Science, Cochrane Library, Scopus, ProQuest, CNKI, Wan Fang, VIP database, and CBMdisc, restricting the establishment date of the databases to October 2024. The ROBINS-I Scale was utilized to evaluate the methodological quality of the included studies. Furthermore, information about CR, PR, SD, PD, ORR, DCR, median OS, median PFS, adverse events (AEs), and other relevant data was obtained. A meta-analysis was performed utilizing a random-effects model and effect size for illness. Results This meta-analysis included six trials, including 238 people with CC. The aggregated outcomes for patients were as follows: CR (0.097, 95% CI: 0.032-0.186), PR (0.465, 95% CI: 0.291-0.638), SD (0.264, 95% CI: 0.124-0.403), PD (0.174, 95% CI: 0.051-0.296), ORR (0.577, 95% CI: 0.354-0.799), DCR (0.784, 95% CI: 0.652-0.916), AEs (all grades: 0.836, 95% CI: 0.629-1.000, ≥grade III: 0.472, 95% CI: 0.111-0.834). The predominant treatment-related adverse events included anemia (≤grade II: 0.295, 95% CI: 0.187-0.402; ≥grade III: 0.124, 95% CI: 0.018-0.230), elevated aspartate aminotransferase (≤grade II: 0.196, 95% CI: 0.013-0.380; ≥grade III: 0.030, 95% CI: 0.007-0.053), neutropenia (≤grade II: 0.206, 95% CI: 0.150-0.261; ≥grade III: 0.114, 95% CI: 0.066-0.162), thrombocytopenia (≤grade II: 0.295, 95% CI: 0.187-0.402), and fatigue (≤grade II: 0.174, 95% CI: 0.046-0.303). Conclusions This meta-analysis demonstrates that camrelizumab is efficacious and well-tolerated in patients with cervical cancer. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42024527065.
Background: The present study aimed to investigate the relationship between prognostic nutritional index (PNI) and peripheral blood neutrophil to lymphocyte ratio (NLR), and the prognosis of patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based therapeutics.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)